ARGX
Price:
$629.99
Market Cap:
$38.03B
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-...[Read more]
Industry
Biotechnology
IPO Date
2017-05-18
Stock Exchange
NASDAQ
Ticker
ARGX
According to argenx SE’s latest financial reports and current stock price. The company's current Enterprise Value is 36.63B. This represents a change of 106.22% compared to the average of 17.76B of the last 4 quarters.
The mean historical Enterprise Value of argenx SE over the last ten years is 7.55B. The current 36.63B Enterprise Value has changed 48.44% with respect to the historical average. Over the past ten years (40 quarters), ARGX's Enterprise Value was at its highest in in the September 2023 quarter at 30.47B. The Enterprise Value was at its lowest in in the June 2020 quarter at -1343074175.87.
Average
7.55B
Median
3.93B
Minimum
104.28M
Maximum
19.81B
Discovering the peaks and valleys of argenx SE Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 240.32%
Maximum Annual Enterprise Value = 19.81B
Minimum Annual Increase = -54.90%
Minimum Annual Enterprise Value = 104.28M
Year | Enterprise Value | Change |
---|---|---|
2023 | 19.72B | -0.47% |
2022 | 19.81B | 19.62% |
2021 | 16.56B | 70.48% |
2020 | 9.72B | 88.13% |
2019 | 5.16B | 91.81% |
2018 | 2.69B | 149.92% |
2017 | 1.08B | 240.32% |
2016 | 316.56M | 7.55% |
2015 | 294.34M | 182.25% |
2014 | 104.28M | -54.90% |
The current Enterprise Value of argenx SE (ARGX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
18.70B
5-year avg
14.20B
10-year avg
7.55B
argenx SE’s Enterprise Value is greater than IVERIC bio, Inc. (5.13B), greater than Blueprint Medicines Corporation (6.13B), greater than Amylyx Pharmaceuticals, Inc. (204.92M), greater than Karuna Therapeutics, Inc. (12.43B), greater than Day One Biopharmaceuticals, Inc. (857.57M), greater than Mirati Therapeutics, Inc. (3.91B), greater than Terns Pharmaceuticals, Inc. (223.81M), greater than Apellis Pharmaceuticals, Inc. (4.22B), greater than Legend Biotech Corporation (5.90B), greater than Zai Lab Limited (2.45B), less than Seagen Inc. (42.84B), greater than Alnylam Pharmaceuticals, Inc. (31.58B), greater than Ascendis Pharma A/S (8.13B), greater than Vaxcyte, Inc. (9.69B), greater than Travere Therapeutics, Inc. (1.86B), greater than Akero Therapeutics, Inc. (1.71B), greater than BeiGene, Ltd. (18.46B),
Company | Enterprise Value | Market cap |
---|---|---|
5.13B | $5.51B | |
6.13B | $5.75B | |
204.92M | $274.19M | |
12.43B | $12.60B | |
857.57M | $1.28B | |
3.91B | $4.12B | |
223.81M | $492.65M | |
4.22B | $4.14B | |
5.90B | $6.02B | |
2.45B | $2.93B | |
42.84B | $43.15B | |
31.58B | $31.37B | |
8.13B | $8.29B | |
9.69B | $10.71B | |
1.86B | $1.49B | |
1.71B | $1.99B | |
18.46B | $20.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like argenx SE using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like argenx SE or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is argenx SE's Enterprise Value?
What is the highest Enterprise Value for argenx SE (ARGX)?
What is the 3-year average Enterprise Value for argenx SE (ARGX)?
What is the 5-year average Enterprise Value for argenx SE (ARGX)?
How does the current Enterprise Value for argenx SE (ARGX) compare to its historical average?